Drug Trial Radar · NCT07193901
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
May 27, 2025
Primary completion
Apr 10, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about: * To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior * To evaluate the safety and pharmacokinetic (PK) characteristics after multiple dose of PRT-042 nasal spray in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior
Conditions
- Major Depressive Disorder (MDD
Interventions
Low Dose PRT042 nasal sprayDrug
two times a week, for 4 weeks
median Dose PRT042 nasal sprayDrug
two times a week, for 4 weeks
high dose PRT042 nasal sprayDrug
two times a week, for 4 weeks
placeboDrug
two times a week, for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours After the First Dose (Day 2)Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
The Sixth Hospital of Peking University
Beijin, China
BEIjing AnDing hospital capital medical university
Beijing, China
Beijing Huilongguan Hospital
Beijing, China
Brain Hospital of Hunan Province
Changsha, China
The Second Xiangya Hospital of Central South University
Changsha, China
The Fourth People's Hospital of Chengdu
Chengdu, China
Hangzhou Seventh People's Hospital
Hangzhou, China
Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center)
Hefei, China
The fourth affiliated hospital of Anhui medical university
Hefei, China
The Affiliated Hospital of Southwest Medical University
Luzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The affiliated Kangning Hospital of Ningbo University
Ningbo, China
Suzhou Guangji Hospital
Suzhou, China
Wuxi Mental Health Center
Wuxi, China
Zhumadian Second People's Hospital(Zhumadian Psychiatric Hospital )
Zhumadian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.